News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
38,129 Results
Type
Article (2436)
Company Profile (39)
Press Release (35654)
Section
Business (14131)
Career Advice (78)
Deals (2080)
Drug Delivery (8)
Drug Development (4111)
Employer Resources (10)
FDA (430)
Job Trends (764)
News (20159)
Policy (1053)
Tag
2024 BioForest Digital (4)
2024 BioMidwest Digital (2)
2024 Biotech Bay Standard (2)
2024 Biotech Beach Digital (1)
2024 Biotech Beach Standard (1)
2024 Lone Star Bio Digital (1)
2024 Pharm Country Digital (1)
2025 Lone Star Bio Digital (1)
Academia (143)
Allergies (4)
Alliances (3469)
ALS (4)
Alzheimer's disease (45)
Antibody-drug conjugate (ADC) (14)
Approvals (432)
Artificial intelligence (9)
Autoimmune disease (2)
Automation (1)
Bankruptcy (11)
Best Places to Work (476)
BIOSECURE Act (2)
Biosimilars (12)
Biotechnology (29)
Bladder cancer (6)
Brain cancer (5)
Breast cancer (17)
Cancer (128)
Cardiovascular disease (4)
Career advice (65)
Career pathing (1)
CAR-T (14)
Cell therapy (41)
Cervical cancer (2)
Clinical research (3180)
Collaboration (88)
Compensation (43)
COVID-19 (180)
CRISPR (7)
C-suite (26)
Cystic fibrosis (2)
Data (101)
Denatured (3)
Depression (3)
Diabetes (9)
Diagnostics (461)
Digital health (1)
Diversity, equity & inclusion (1)
Drug discovery (13)
Drug pricing (7)
Duchenne muscular dystrophy (12)
Earnings (4240)
Editorial (3)
Employer branding (1)
Employer resources (8)
Events (6006)
Executive appointments (85)
FDA (472)
Featured Employer (3)
Funding (74)
Gene editing (14)
Gene therapy (17)
GLP-1 (60)
Government (149)
Healthcare (704)
Huntington's disease (3)
IgA nephropathy (3)
Immunology and inflammation (15)
Indications (2)
Infectious disease (185)
Inflammatory bowel disease (11)
Inflation Reduction Act (6)
Influenza (4)
Intellectual property (10)
Interviews (7)
IPO (991)
IRA (7)
Job creations (292)
Job search strategy (62)
Kidney cancer (4)
Labor market (3)
Layoffs (36)
Leadership (1)
Legal (213)
Liver cancer (5)
Lung cancer (15)
Lymphoma (3)
Management (4)
Manufacturing (18)
MASH (4)
Medical device (306)
Medtech (306)
Mergers & acquisitions (1150)
Metabolic disorders (32)
Multiple sclerosis (6)
Neurodegenerative disease (7)
Neuropsychiatric disorders (3)
Neuroscience (87)
NextGen: Class of 2025 (352)
Non-profit (155)
Northern California (330)
Now hiring (4)
Obesity (15)
Opinion (15)
Ovarian cancer (10)
Pain (8)
Pancreatic cancer (3)
Parkinson's disease (4)
Partnered (1)
Patents (19)
Patient recruitment (2)
Peanut (1)
People (5631)
Pharmaceutical (5)
Phase I (1370)
Phase II (1596)
Phase III (849)
Pipeline (70)
Podcasts (4)
Policy (11)
Postmarket research (30)
Preclinical (588)
Press Release (2)
Prostate cancer (3)
Psychedelics (2)
Radiopharmaceuticals (12)
Rare diseases (21)
Real estate (419)
Recruiting (5)
Regulatory (803)
Reports (6)
Research institute (142)
Resumes & cover letters (10)
Schizophrenia (10)
Series A (24)
Series B (5)
Service/supplier (2)
Sickle cell disease (1)
Southern California (338)
Special edition (1)
Spinal muscular atrophy (2)
Sponsored (1)
Startups (489)
Stomach cancer (1)
Supply chain (4)
The Weekly (1)
United States (1625)
Vaccines (28)
Venture capitalists (7)
Webinars (2)
Weight loss (11)
Women's health (1)
Worklife (1)
Date
Today (20)
Last 7 days (60)
Last 30 days (224)
Last 365 days (2567)
2025 (620)
2024 (2612)
2023 (2859)
2022 (3752)
2021 (4053)
2020 (3475)
2019 (2071)
2018 (1559)
2017 (1799)
2016 (1632)
2015 (1846)
2014 (1375)
2013 (1192)
2012 (1397)
2011 (1333)
2010 (1181)
Location
Africa (43)
Alabama (1)
Arizona (14)
Asia (1862)
Australia (299)
California (772)
Canada (129)
China (38)
Colorado (19)
Connecticut (10)
Delaware (3)
Europe (3804)
Florida (43)
Georgia (6)
Idaho (3)
Illinois (14)
India (1)
Indiana (30)
Japan (7)
Kansas (12)
Maryland (24)
Massachusetts (283)
Michigan (8)
Minnesota (14)
Missouri (3)
Nebraska (1)
Nevada (2)
New Hampshire (2)
New Jersey (65)
New York (46)
North Carolina (88)
Northern California (330)
Ohio (25)
Oklahoma (2)
Oregon (4)
Pennsylvania (44)
Rhode Island (2)
South America (40)
South Carolina (1)
Southern California (338)
Tennessee (2)
Texas (66)
Utah (2)
Virginia (5)
Washington D.C. (1)
Washington State (44)
Wisconsin (6)
38,129 Results for "spruce biosciences".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Bay
Spruce Biosciences to Participate in the Jefferies Global Healthcare Conference
Spruce Biosciences, Inc will present at the Jefferies Global Healthcare Conference on June 5, 2024, at 5:00 p.m. ET.
May 23, 2024
·
1 min read
Business
Spruce Biosciences Recognized as a Bay Area Best Place to Work
Spruce Biosciences, Inc. announced that the San Francisco Business Times and the Silicon Valley Business Journal have recognized the company as a Best Place to Work in 2024.
June 6, 2024
·
2 min read
Biotech Bay
Spruce Biosciences to Participate in May 2024 Investor Conferences
Spruce Biosciences, Inc. announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will participate in two upcoming investor conferences taking place in May.
May 1, 2024
·
1 min read
Business
Spruce Biosciences and HMNC Brain Health Announce Strategic Collaboration to Develop Treatment for Major Depressive Disorder (MDD)
Spruce Biosciences, Inc. and HMNC Brain Health GmbH (“HMNC”), announced today a strategic collaboration to develop Spruce’s investigational product candidate, tildacerfont, a second-generation CRF1 receptor antagonist, with HMNC’s companion diagnostic, the proprietary Cortibon Genetic Selection Tool (“Cortibon”), for the treatment of MDD.
June 4, 2024
·
7 min read
Biotech Bay
Spruce Biosciences Announces Poster Presentations at the 2024 Annual Meeting of the Endocrine Society
Spruce Biosciences, Inc today announced that three submitted abstracts were accepted for the 106th Annual Meeting of the Endocrine Society (ENDO 2024) taking place June 1-4, 2024, in Boston.
May 22, 2024
·
3 min read
Press Releases
Spruce Biosciences to Participate in the Guggenheim Securities Healthcare Innovation Conference
October 29, 2024
·
1 min read
Press Releases
Spruce Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
November 11, 2024
·
9 min read
Business
Spruce Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the first quarter ended March 31, 2024 and provided corporate updates.
May 13, 2024
·
11 min read
Press Releases
Spruce Biosciences Announces Topline Results from CAHmelia-204 in Adult CAH and CAHptain-205 in Adult and Pediatric CAH
December 10, 2024
·
8 min read
Drug Development
Spruce Biosciences Presented Phase 2 POWER Study Results of Tildacerfont for the Treatment of Polycystic Ovary Syndrome at ENDO 2024
Spruce Biosciences, Inc. (Nasdaq: SPRB) presented results from its Phase 2 POWER study of tildacerfont, a second-generation CRF1 receptor antagonist, for the treatment of polycystic ovary syndrome (PCOS) at the 2024 Annual Meeting of the Endocrine Society (ENDO 2024).
June 3, 2024
·
8 min read
1 of 3,813
Next